house · trading 2015-11-02 → 2024-11-21
*Notional-weighted price return on disclosed buys from the last ~3 years, marked to the latest close — open positions, per-share (share counts aren't disclosed, so this is price performance, not realized $ P&L).
By recent-buy return, Doug Lamborn ranks #40 of 122 lawmakers — better than 67% of Congress.
▮ buys · ▮ sells
| Date | Ticker | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2020-12-17 | NET | BUY | $1K–$15K | $81.82 | $308.23 2026-08-27 | +276.7% |
| 2020-10-23 | SP | BUY | $1K–$15K | — | — | — |
| 2020-10-06 | SP | BUY | $1K–$15K | — | — | — |
| 2019-11-11 | NTAP | BUY | $1K–$15K | $59.87 | $190.64 2026-08-27 | +218.4% |
| 2019-09-16 | NTAP | BUY | $1K–$15K | $56.84 | $190.64 2026-08-27 | +235.4% |
| 2019-07-15 | SP | BUY | $1K–$15K | — | — | — |
| 2019-05-08 | NTAP | BUY | $1K–$15K | $68.92 | $190.64 2026-08-27 | +176.6% |
| 2019-04-15 | NTAP | BUY | $1K–$15K | $76.16 | $190.64 2026-08-27 | +150.3% |
| 2018-09-28 | NTAP | SELL | $1K–$15K | $85.89 | $190.64 2026-08-27 | +25.7% rt |
| 2018-09-28 | NTAP | BUY | $1K–$15K | $85.89 | $190.64 2026-08-27 | +122.0% |
| 2018-09-05 | NXTAPP | BUY | $1K–$15K | — | — | — |
| 2018-05-01 | NTAP | SELL | $1K–$15K | $67.85 | $190.64 2026-08-27 | +8.0% rt |
| 2018-04-23 | NTAP | BUY | $1K–$15K | $68.35 | $190.64 2026-08-27 | +178.9% |
| 2018-03-22 | NTAP | SELL | $1K–$15K | $62.16 | $190.64 2026-08-27 | +6.9% rt |
| 2018-03-19 | NTAP | BUY | $1K–$15K | $62.84 | $190.64 2026-08-27 | +203.4% |
| 2018-02-06 | NTAP | BUY | $1K–$15K | $58.14 | $190.64 2026-08-27 | +227.9% |
| 2017-12-05 | NTAP | SELL | $1K–$15K | $56.14 | $190.64 2026-08-27 | +28.7% rt |
| 2017-12-01 | NTAP | SELL | $1K–$15K | $56.41 | $190.64 2026-08-27 | +52.0% rt |
| 2017-11-21 | NTAP | SELL | $1K–$15K | $55.08 | $190.64 2026-08-27 | +69.5% rt |
| 2017-11-07 | NTAP | SELL | $1K–$15K | $44.65 | $190.64 2026-08-27 | +37.7% rt |
| 2017-10-31 | NTAP | SELL | $1K–$15K | $44.42 | $190.64 2026-08-27 | +30.9% rt |
| 2017-10-27 | NTAP | SELL | $1K–$15K | $44.01 | $190.64 2026-08-27 | +29.9% rt |
| 2017-10-16 | NTAP | SELL | $1K–$15K | $43.72 | $190.64 2026-08-27 | +26.0% rt |
| 2017-10-14 | NTAP | BUY | $1K–$15K | $43.63 | $190.64 2026-08-27 | +336.9% |
| 2016-11-21 | NTAP | BUY | $1K–$15K | $37.12 | $190.64 2026-08-27 | +413.6% |
| 2016-11-08 | NTAP | BUY | $1K–$15K | $32.49 | $190.64 2026-08-27 | +486.8% |
| 2016-11-02 | NTAP | BUY | $1K–$15K | $32.42 | $190.64 2026-08-27 | +488.0% |
| 2016-10-31 | NTAP | BUY | $1K–$15K | $33.94 | $190.64 2026-08-27 | +461.7% |
| 2016-10-13 | NTAP | BUY | $1K–$15K | $33.87 | $190.64 2026-08-27 | +462.9% |
| 2016-08-22 | NTAP | SELL | $1K–$15K | $34.71 | $190.64 2026-08-27 | +37.1% rt |
| 2016-08-19 | NTAP | BUY | $1K–$15K | $34.71 | $190.64 2026-08-27 | +449.2% |
| 2016-06-20 | NTAP | BUY | $1K–$15K | $25.31 | $190.64 2026-08-27 | +653.2% |
| 2015-11-17 | GSK | SELL | $1K–$15K | $40.63 | $50.27 2026-08-27 | -23.7% exit |
| 2015-11-12 | GSK | SELL | $1K–$15K | $40.05 | $50.27 2026-08-27 | -25.5% exit |
| 2015-11-07 | NAT | SELL | $1K–$15K | $15.02 | $6.76 2026-08-27 | -2.1% rt |
| 2015-11-07 | GSK | SELL | $1K–$15K | $41.92 | $50.27 2026-08-27 | -2.8% rt |
| 2015-11-02 | NAT | BUY | $1K–$15K | $15.34 | $6.76 2026-08-27 | -55.9% |
| 2015-11-02 | GSK | BUY | $1K–$15K | $43.11 | $50.27 2026-08-27 | +16.6% |
| NTAP | SELL | $1K–$15K | — | — | — exit | |
| NTAP | BUY | $1K–$15K | — | — | — | |
| NTAP | BUY | $1K–$15K | — | — | — | |
| META | BUY | $1K–$15K | — | — | — |
Return: buys are marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (how the stock moved after the sale, seller's perspective).
| Member | Shared tickers |
|---|---|
| Rohit Khanna | 5 · NTAP, SP, META, GSK, SPY |
| John Boozman | 4 · NTAP, META, GSK, SPY |
| Mike Kelly | 4 · SP, META, GSK, SPY |
| Josh Gottheimer | 3 · NET, META, SPY |
| Thomas R Carper | 3 · NTAP, GSK, SPY |
| Rob Bresnahan | 3 · NET, META, SPY |
| James B. Renacci | 2 · GSK, SPY |
| Thomas H Tuberville | 2 · META, GSK |
| Virginia Foxx | 2 · GSK, NAT |
| K. Michael Conaway | 2 · GSK, SPY |
| Kurt Schrader | 2 · GSK, SPY |
| David P. Roe | 2 · META, GSK |